Cutting the patch can disrupt the delivery mechanism and may cause overdosing
Below are common questions that can help clarify what sets each program apart
It gives us pause to say for an average employer group out there if youre investing in this medication for your employees, dont expect to see a return in year one. According to Joseph Leach, M.D., Senior Vice President and Chief Medical Officer at Prime, We will need results of ongoing, multi-year studies to see if this treatment has downstream impacts on other health conditions, including cardiovascular events and diabetes development prevention, which are key benefits to weight loss management
Rarely, there may be risks of pancreatitis or thyroid C-cell tumors, so medical supervision is important
The findings suggest that GLP-1RAs may help address several of these treatment goals
It is worth stressing that this is early, developing research, not a proven treatment